<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2807245668
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Malaquon
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ATOVAQUONE,PROGUNAIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250,100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        93.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; V" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – V
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        P01BB51
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Malaquon belongs to a group of medicines called antimalarials. It contains two active ingredients, atovaquone and proguanil hydrochloride<br />Malaquon is used to:<br />. Prevent malaria<br />. Treat malaria<br />Malaria is spread by the bite of an infected mosquito, which passes the malaria parasite (Plasmodium falciparum) into the bloodstream. Atovaquone/Proguanil hydrochloride prevents malaria by killing this parasite. For people who are already infected with malaria, Atovaquone/Proguanil hydrochloride also kills these parasites.<br />Protect yourself from catching malaria.<br />People of any age can get malaria. It is a serious disease, but is preventable.<br />As well as taking Malaquon, it is very important that you also take steps to avoid being bitten by mosquitoes:<br />&bull; Use insect repellent on exposed areas of the skin<br />&bull; Wear light coloured clothing that covers most of the body, especially after sunset as this is the time when mosquitoes are most active.<br />&bull; Sleep in a screened room or under a mosquito net impregnated with insecticide<br />&bull; Close windows and doors at sunset, if they are not screened<br />&bull; Consider using an insecticide (mats, spray, plug-ins) to clear a room of insects or to deter mosquitoes from entering the room<br />If you need further advice, talk to your doctor or pharmacist.<br />It is still possible to get malaria after taking the necessary precautions. Some types of malaria infection take a long time to cause symptoms, so the illness may not start until several days, weeks or even months after returning from abroad. See a doctor immediately if you get symptoms such as high temperature, headache, shivering and tiredness after returning home.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Malaquon:<br />&bull; if you are allergic to atovaquone, proguanil hydrochloride or any of the ingredients of this medicine (listed in section 6).<br />&bull; for preventing malaria, if you have severe kidney disease.<br />Tell your doctor if either of these apply to you.<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking Malaquon</p><p>Children<br />Atovaquone/Proguanil hydrochloride 250 mg/100 mg film-coated tablets are not recommended in children who weigh less than 11 kg. Another strength of atovaquone/proguanil tablets may be available which are more suitable for children who weigh less than 11 kg.<br />Other medicines and Malaquon<br />Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including medicines you&rsquo;ve bought without a prescription.<br />Some medicines can affect the way Malaquon works, or Malaquon itself can strengthen or weaken the effectiveness of other medicines taken at the same time. These include:<br />&bull;metoclopramide, used to treat nausea and vomiting.<br />&bull; the antibiotics, tetracycline, rifampicin and rifabutin<br />&bull; efavirenz or certain highly active protease-inhibitors used to treat HIV.<br />&bull; warfarin and other medicines that stop blood clotting<br />&bull; etoposide used to treat cancer.<br />Tell your doctor if you are taking any of these. Your doctor may decide that Malaquon isn&rsquo;t suitable for you, or that you need extra checkups while you&rsquo;re taking it.<br />Remember to tell your doctor if you start taking any other medicines while you&rsquo;re taking Malaquon.<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.<br />Atovaquone/Proguanil hydrochloride should not be used during pregnancy unless your doctor recommends it.<br />You should not breast-feed while taking Atovaquone/Proguanil hydrochloride, as the ingredients&nbsp;of Atovaquone/Proguanil hydrochloride may pass into breast milk and may harm your baby.</p><p>Driving and using machines<br />If you feel dizzy, do not drive.<br />Malaquon makes some people feel dizzy. If this happens to you, do not drive, use machines or take part in activities where you may put yourself or others at risk.<br />Atovaquone/Proguanil hydrochloride contains lactose<br />If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.<br />For preventing malaria:<br />The recommended dose for adults and children weighing at least 40 kg is 1 tablet once a day, taken as below. Atovaquone/Proguanil hydrochloride is not recommended for preventing malaria in children, or in adults or adolescents who weigh less than 40 kg. There may be different type of tablets available in your country for preventing malaria in children and adults who weigh less than 40 kg.<br />&bull; start taking Atovaquone/Proguanil hydrochloride 1 to 2 days before travelling to an area which has malaria<br />&bull; continue taking it every day during your stay<br />&bull; continue taking it for another 7 days after your return to a malaria-free area<br />For treating malaria:<br />To treat malaria:<br />The recommended dose for adults is 4 tablets once a day for 3 days.<br />For children weighing 11 kg or more the dose depends on their bodyweight:<br />11-20 kg &ndash; 1 tablet once a day for 3 days<br />21-30 kg &ndash; 2 tablets once a day for 3 days<br />31-40 kg &ndash; 3 tablets once a day for 3 days<br />over 40 kg &ndash; dose as for adults<br />Not&nbsp;recommended for treating malaria in children who weigh less than 11 kgs.<br />For children who weigh less than 11 kg talk to your doctor. There may be different type of tablets available in your country for children, containing less atovaquone and proguanil hydrochloride<br />Method of administration<br />For oral use.<br />Take Atovaquone/Proguanil hydrochloride with food or a milky drink, where possible.<br />Take Atovaquone/Proguanil hydrochloride at the same time each day.<br />If you are sick (vomit):<br />For preventing malaria:<br />&bull; If you are sick (vomit) within 1 hour of taking your Atovaquone/Proguanil hydrochloride tablet, take another dose straight away.<br />&bull; It is important to take the full course of Atovaquone/Proguanil hydrochloride. If you have to take extra tablets due to sickness, you may need another prescription.<br />&bull; If you have been vomiting, it is especially important to use extra protection, such as repellents and bed nets. Atovaquone/Proguanil hydrochloride may not be as effective, as the amount absorbed will be reduced.<br />For treating malaria:<br />&bull; If you have vomiting and diarrhea, tell your doctor, you will need regular blood tests. Atovaquone/Proguanil hydrochloride will not be as effective, as the amount absorbed will be reduced. The tests will check whether the malaria parasite is being cleared from your blood.<br />If you take more Malaquon than you should<br />Contact a doctor or pharmacist for advice. If possible, show them the Malaquon pack.<br />If you forget to take Malaquon<br />It is very important that you take the full course of Malaquon.<br />If you forget to take a dose, don&rsquo;t worry. Just take your next dose as soon as you remember. Then continue your treatment as before.<br />Do not take a double dose to make up for a forgotten dose.<br />If you stop taking Malaquon<br />Do not stop taking Atovaquone/Proguanil hydrochloride without advice.<br />Keep taking Atovaquone/Proguanil hydrochloride for 7 days after you return to a malaria-free area. Take the full course of Atovaquone/Proguanil hydrochloride for maximum protection. Stopping early puts you at risk of getting malaria, as it takes 7 days to ensure that any parasites that may be in your blood following a bite from an infected mosquito are killed.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.4.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Look out for the following severe reactions. They have occurred in a small number of people, but their exact frequency is unknown.<br />Severe allergic reactions - signs include:<br />&bull; rash and itching<br />&bull; sudden wheezing, tightness of the chest or throat, or difficulty breathing<br />&bull; swollen eyelids, face, lips, tongue or other part of the body.<br />Contact a doctor immediately if you get any of these symptoms and stop taking Malaquon.<br />Severe skin reactions<br />&bull; skin rash, which may blister and looks like small targets (central dark spots, surrounded by paler area with a dark ring around the edge) (erythema multiforme)<br />&bull; severe widespread rash with blisters and peeling skin, particularly occurring around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome).<br />If you notice any of these symptoms contact a doctor urgently.<br />Most of the other side effects reported have been mild and have not lasted very long.<br />Very common side effects (may affect more than 1 in 10 people):<br />&bull; headache<br />&bull; feeling sick and being sick (nausea and vomiting)<br />&bull; stomach pain<br />&bull; diarrhea.<br />Common side effects (may affect up to 1 in 10 people):<br />&bull; dizziness<br />&bull; sleeping problems (insomnia)<br />&bull; strange dreams<br />&bull; depression<br />&bull; loss of appetite<br />&bull; fever<br />&bull; rash which may be itchy<br />&bull; cough<br />Common side effects, which may show up in your blood tests are:<br />&bull; reduced numbers of red blood cells (anaemia) which can cause tiredness, headaches and shortness of breath<br />&bull; reduced numbers of white blood cells (neutropenia) which may make you more likely to catch infections<br />&bull; low levels of sodium in the blood (hyponatremia)<br />&bull; an increase in liver enzymes.<br />Uncommon side effects (may affect up to 1 in 100 people):<br />&bull; anxiety<br />&bull; an unusual awareness of abnormal beating of the heart (palpitations)<br />&bull; swelling and redness of the mouth<br />&bull; hair loss<br />Uncommon side effects that may show up in your blood tests:<br />&bull; An increase in amylase (an enzyme produced in the pancreas).<br />Rare side effects<br />These may affect up to 1 in 1,000 people:<br />&bull; seeing or hearing things that are not there (hallucinations)<br />Not known (frequency cannot be estimated from the available data):<br />Other side effects have occurred in a small number of people but their exact frequency is unknown.<br />&bull; Inflammation of the liver(hepatitis)<br />&bull; blockage of the bile ducts (cholestatis)<br />&bull; increase in heart rate (tachycardia)<br />&bull; inflammation of the blood vessels (vasculitis) which may be visible as red or purple raised spots on the skin but can affect other parts of the body<br />&bull; fits (seizures)<br />&bull; panic attacks, crying<br />&bull; nightmares<br />&bull; severe mental health problem in which the person loses contact with reality and is unable to think and judge clearly<br />&bull; indigestion<br />&bull; mouth ulcers<br />&bull; blisters<br />&bull; peeling skin<br />&bull; increased sensitivity of the skin to sunlight.<br />Other side effects that may show up in your blood tests:<br />&bull; A decrease in all types of blood cells (pancytopenia</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />&bull; Store below 30&deg;C.<br />&bull; Store in the original package in order to protect from moisture.<br />&bull; Keep this medicine out of the sight and reach of children.<br />&bull; Do not use this medicine after the expiry date which is stated on the pack after EXP. The expiry date refers to the last day of the month.<br />&bull; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Atovaquone and Proguanil Hydrochloride<br />The other ingredients are: Cellulose, microcrystalline (Avicel PH 101), Low-Substituted Hydroxylpropyl cellulose (L-HPC LH 21), Sodium starch glycolate (Primojel), Silica colloidal anhydrous (Aerosil 200), Povidone (kollidon-30), Poloxamers (Lutrol F 68), Low-Substituted Hydroxylpropyl cellulose (L-HPC LH 11), Magnesium Stearate and Purified Water.<br />Film coating composition: HPMC 2910/Hypromellose 3cP, Titanium Dioxide, HPMC 2910/Hypromellose 15cP, HPMC 2910/Hypromellose 50 cP, Macrogol/PEG 8000, Macrogol/PEG 400, Iron Oxide Red.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                b. What Malaquon looks like and contents of pack
Atovaquone and Proguanil hydrochloride Tablets 250mg/100mg:
Pink, round, biconvex film coated tablets, debossed with 'H' on one side and '175' on the other side.
How supplied:
Atovaquone and Proguanil hydrochloride 250mg/100mg Tablets are supplied in Blister of 10’s pack.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Saudi Amarox Industrial Company<br />Al Jamiah Street, Al Malaz District<br />Riyadh 12629, Saudi Arabia.<br />Tel &amp; Fax: +966 11 226 8850.<br />Manufacture<br />Hetero Labs Limited Unit V, India</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                April 2024.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ینتمي مالاكون ۲٥۰ ملجرام / ۱۰۰ ملجرام إلى مجموعة من الأدویة تسمى مضادات الملاریا. یحتوي على مادتین فعالتین ، أتوفاكوین و<br />بروجوانیل ھیدروكلورید. و یستخدم مالاكون ۲٥۰ ملجرام / ۱۰۰ ملجرام أقراص فیما یلي:<br />&bull; للوقایة من الملاریا<br />&bull; لعلاج الملاریا<br />تعلیمات الجرعة لكل استخدام موجودة في القسم ۳، طریقة استخدام مالاكون أقراص<br />Plasmodium falciparum) تنتشر الملاریا عن طریق لدغة بعوضة مصابة ، والتي تنقل طفیلي الملاریا ) إلى مجرى الدم. یعمل<br />مالاكون على منع الإصابة بالملاریا عن طریق قتل ھذا الطفیل. بالنسبة للأشخاص المصابین بالفعل بالملاریا ، فإن أقراص مالاكون تقتل<br />أیضًا ھذه الطفیلیات.<br />احم نفسك من الإصابة بالملاریا<br />یمكن أن یصاب الناس في أي عمر بالملاریا. إنھ مرض خطیر ولكن یمكن الوقایة منھ. بالإضافة إلى تناول أقراص مالاكون، من المھم<br />جدًا أن تتخذ أیضًا خطوات لتجنب لدغ البعوض.<br />&bull; استخدم طارد الحشرات على المناطق المكشوفة من الجلد.<br />&bull; ارتداء ملابس فاتحة تغطي معظم الجسم ، خاصة بعد غروب الشمس لأن ھذا ھو الوقت الذي یكون فیھ البعوض أكثر نشاطًا.<br />&bull; النوم في غرفة مغلقة أو تحت ناموسیة مشربة بمبید حشري.<br />&bull; أغلق النوافذ والأبواب عند غروب الشمس إذا لم تكن مغطاة.<br />&bull;<br />ضع في اعتبارك استخدام مبید حشري (حصائر ، رذاذ ، مكونات إضافیة) لتنظیف الغرفة من الحشرات أو لردع البعوض من<br />دخول الغرفة.<br />إذا كنت بحاجة إلى مزید من النصائح ، تحدث إلى طبیبك أو الصیدلي<br />لا یزال من الممكن الإصابة بالملاریا بعد اتخاذ الاحتیاطات اللازمة. تستغرق بعض أنواع عدوى الملاریا وقتاً طویلا لتسبب الأعراض ،<br />لذلك قد لا یبدأ المرض إلا بعد عدة أیام أو أسابیع أو حتى أشھر بعد العودة من الخارج.<br />راجع الطبیب فورًا إذا ظھرت علیك أعراض مثل ارتفاع درجة الحرارة والصداع والرعشة والتعب بعد العودة إلى المنزل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تستخدم مالاكون أقراص<br />&bull; إذا كنت تعاني من حساسیة تجاه أتوفاكوین و / أو بروجوانیل ھیدروكلورید أو أي من مكونات ھذا الدواء (المدرجة في القسم<br />.(٦<br />&bull; للوقایة من الملاریا ، إذا كان لدیك مرض كلوي حاد .<br />أخبر طبیبك إذا كان أي من ھذه ینطبق علیك.<br />انتبھ جیدا عند استعمال مالاكون<br />تحدث إلى طبیبك أو الصیدلي قبل تناول مالاكون إذا:<br />&bull; إذا كنت تعاني من مرض شدید في الكلى<br />&bull;إذا كان یتلقى طفلك العلاج من الملاریا ویزن أقل من ۱۱ كیلوجرام. ھناك قوة أقراص أخرى لعلاج الأطفال الذین یقل وزنھم عن ۱۱<br />.( كجم (انظر القسم ۳<br />أخبر طبیبك أو الصیدلي إذا كان أي من ھذه ینطبق علیك.<br />الأدویة الأخرى وتناول مالاكون أقراص<br />أخبر طبیبك أو الصیدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدویة أخرى، بما في ذلك الأدویة التي اشتریتھا دون وصفة<br />طبیة.<br />فبعض الأدویة یمكن أن تؤثر على طریقة عمل أقراص مالاكون أو أقراص مالاكون نفسھا یمكن أن یقوي أو یضعف من فعالیة الأدویة<br />الأخرى التي یتم تناولھا في نفس الوقت. وتشمل ھذه:<br />&bull; میتوكلوبرامید ، ویستعمل لعلاج الغثیان والقيء<br />&bull; المضادات الحیویة مثل التتراسیكلین والریفامبیسین والریفابوتین<br />&bull; إیفافیرینز أو بعض مثبطات الأنزیم البروتیني النشطة للغایة المستخدمة لعلاج فیروس نقص المناعة البشریة<br />&bull; إندینافیر یستعمل لعلاج فیروس نقص المناعة البشریة<br />&bull; الوارفارین والأدویة الأخرى التي توقف تخثر الدم<br />&bull; إیتوبوزید یستعمل لعلاج السرطان.<br />أخبر طبیبك إذا كنت تتناول أیاً من ھذه. قد یقرر طبیبك أن أقراص مالاكون لیست مناسبة لك ، أو أنك بحاجة إلى فحوصات إضافیة أثناء<br />تناولھا.<br />تذكر أن تخبر طبیبك إذا بدأت في تناول أي أدویة أخرى أثناء تناول أقراص مالاكون.<br />تناول مالاكون مع الطعام والشراب<br />تناول مالاكون أقراص مع الطعام أو المنتجات الحلیبیة ، حیثما أمكن. سیؤدي ذلك إلى زیادة كمیة المواد الفعالة من التي یمكن لجسمك<br />امتصاصھا ، ویجعل علاجك أكثر فعالیة.<br />الحمل والرضاعة<br />إذا كنت حاملا أو إذا كنت تخططین الحمل ، فلا تتناولین أقراص مالاكون إلا إذا أوصى طبیبك بذلك.<br />إسألي طبیبك أو الصیدلي للحصول على المشورة قبل تناول أقراص مالاكون. لا ترضعي طفلك أثناء تناول أقراص مالاكون ، لأن<br />مكونات أقراص مالاكون قد تنتقل إلى حلیب الثدي وقد تضر بطفلك.<br />القیادة واستخدام الآلات<br />إذا شعرت بالدوار ، فلا تقود. مالاكون أقراص تجعل بعض الناس یشعرون بالدوار. إذا حدث ھذا لك ، فلا تقود السیارة أو تستخدم<br />الآلات أو تشارك في الأنشطة التي قد تعرض نفسك أو الآخرین فیھا للخطر.<br />مالاكون یحتوي على الصودیوم<br />یحتوي ھذا الدواء على أقل من ۱ ملیمول صودیوم ( ۲۳ ملجرام) لكل قرص، وھذا یعني أنھ خالٍ من الصودیوم بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یجب أن تتناول أقراص مالاكون دائمًا تمامًا كما أخبرك طبیبك. استشر طبیبك أو الصیدلي إذا لم تكن متأكدًا.<br />تناول مالاكون أقراص مع الطعام أو مشروب حلیبي ، حیثما أمكن ذلك. من الأفضل تناول أقراص مالاكون في نفس الوقت كل یوم.<br />للوقایة من الملاریا<br />&bull; إذا كنت مصابا بالإعیاء (وحدث القيء) خلال ساعة واحدة من تناول قرص مالاكون، فتناول جرعة أخرى على الفور.<br />&bull; من المھم تناول الجرعة الكاملة من مالاكون. إذا كان علیك تناول أقراص إضافیة بسبب المرض ، فقد تحتاج إلى وصفة طبیة<br />أخرى.<br />&bull; إذا كنت تتقیأ ، فمن المھم بشكل خاص استخدام واقي إضافي ، مثل المواد الطاردة للحشرات والناموسیات. مالاكون قد لا<br />تكون فعالة لأن الكمیة الممتصة ستقل.<br />أثناء العلاج من الملاریا:<br />&bull; إذا كنت تعاني من القيء والإسھال ، أخبر طبیبك ، سوف تحتاج إلى فحوصات دم منتظمة. مالاكون لن تكون فعالة لأن الكمیة<br />الممتصة ستقل. ستفحص الاختبارات ما إذا كان قد تم تطھیر دمك من طفیلي الملاریا .<br />للوقایة من الملاریا:<br />الجرعة المعتادة للبالغین والمراھقین ھي قرص واحد مرة واحدة في الیوم، على النحو التالي.<br />لا ینصح بھ للوقایة من الملاریا عند الأطفال أو البالغین الذین یقل وزنھم عن ٤۰ كجم. یوصى باستخدام أقراص مالاكون للأطفال<br />للوقایة من الملاریا لدى البالغین والأطفال الذین یقل وزنھم عن ٤۰ كجم.<br />للوقایة من الملاریا لدى البالغین :<br />&bull; ابدأ بتناول مالاكون قبل یوم أو یومین من السفر إلى منطقة تنتشر فیھا الملاری ا<br />&bull; استمر في تناولھ كل یوم أثناء إقامتك<br />&bull; استمر في تناولھ لمدة ۷ أیام أخرى بعد عودتك إلى منطقة خالیة من الملاریا.<br />لعلاج الملاریا:<br />الجرعة المعتادة للبالغین ھي ٤ أقراص مرة في الیوم لمدة ۳ أیام. للأطفال بوزن ۱۱ ك یلوجرام أو أكثر:<br />من ۱۱ إلى ۲۰ ك یلو جرام - قرص واحد مرة واحدة یومیاً لمدة ۳ أیام<br />من ۲۱ إلى ۳۰ ك یلو جرام - قرصین مرة واحدة یومیاً لمدة ۳ أیام<br />من ۳۱ إلى ٤۰ ك یلو جرام &ndash; ۳ أقراص مرة واحدة یومیاً لمدة ۳ أیام<br />&bull; أكثر من ٤۰ كیلو جرام &ndash; الجرعة للبالغین.</p><p>مالاكون أقراص لا ینصح بھا لعلاج الملاریا عند الأطفال الذین یقل وزنھم عن ۱۱ كیلو جرام.<br />بالنسبة للأطفال الذین یقل وزنھم عن ۱۱ كیلوجرام تحدث إلى طبیبك. قد یكون ھناك نوع مختلف من مالاكون متوفر في بلدك<br />تناول جرعة زائدة من مالاكون أقراص<br />اتصل بطبیب أو صیدلي للحصول على المشورة. إذا أمكن ، أظھر لھم علبة أقراص مالاكون<br />إذا نسیت أن تتناول مالاكون<br />من المھم جدًا أن تتناول جرعة مالاكون كاملة. إذا نسیت تناول جرعة ، فلا تقلق. فقط تناول جرعتك التالیة بمجرد أن تتذكرھا. ثم استمر<br />في علاجك كما كان من قبل. لا تتناول جرعة مضاعفة لتعویض الجرعة الفائتة.<br />التوقف عن تناول مالاكون<br />لا تتوقف عن تناول مالاكون أقراص بدون نصیحة<br />استمر في تناول أتوفاكوین و برو جوانیل ھیدروكلورید لمدة ۷ أیام بعد عودتك إلى منطقة خالیة من الملاریا. تناول الدورة العلاجیة<br />الكاملة من أتوفاكوین و بروجوانیل ھیدروكلورید للحصول على أقصى حمایة. یعرضك التوقف المبكر لخطر الإصابة بالملاریا ، حیث<br />یستغرق الأمر ۷ أیام للتأكد من قتل أي طفیلیات قد تكون في دمك بعد لدغة بعوضة مصابة.<br />إذا كان لدیك أي أسئلة أخرى حول استخدام ھذا المنتج ، اسأل طبیبك أو الصیدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جمیع الأدویة ، یمكن أن یسبب ھذا الدواء آثارًا جانبیة ، على الرغم من عدم حدوثھا لدى الجمیع.<br />ینبغي التحقق من ردود الفعل الشدیدة التالیة. لقد حدثت في عدد قلیل من الناس ، لكن معدل حدوثھا غیر معروف.<br />ردود الفعل التحسسیة الشدیدة - تشمل العلامات:<br />&bull; طفح جلدي وحكة<br />&bull; صفیر مفاجئ أو ضیق في الصدر أو الحلق أو صعوبة في التنف س<br />&bull; انتفاخ الجفون والوجھ والشفتین واللسان أو جزء آخر من الجسم.<br />اتصل بالطبیب على الفور إذا ظھرت علیك أي من ھذه الأعراض. التوقف عن تناول مالاكون.<br />تفاعلات جلدیة شدیدة:<br />&bull; طفح جلدي ، قد ینفخ ویبدو وكأنھ بثور صغیرة (بقع داكنة مركزیة ، محاطة بمنطقة شاحبة مع حلقة داكنة حول الحافة)<br />(حمامي عدیدة الأشكال).<br />&bull; طفح جلدي شدید منتشر مع ظھور بثور وتقشر جلدي ، خاصة التي تظھر حول الفم والأنف والعینین والأعضاء التناسلیة<br />(متلازمة ستیفنز - جونسون).<br />إذا لاحظت أیاً من ھذه الأعراض ، فاتصل بالطبیب على وجھ السرعة .<br />معظم الآثار الجانبیة الأخرى التي تم الإبلاغ عنھا كانت خفیفة ولم تستمر طویلا.ً<br />شائعة جدًا:<br />تؤثر على أكثر من ۱ من كل ۱۰ مستخدمین<br />&bull; صداع الراس<br />&bull; الشعور بالمرض والإعیاء (الغثیان والقيء).<br />&bull; آلام في المعد ة</p><p>&bull;<br />إسھال<br />شائع:<br />یؤثر على ۱ إلى ۱۰ مستخدمین<br />&bull; دوار<br />&bull; مشاكل النوم (الأرق).<br />&bull; احلام غریبة<br />&bull; كآبة<br />&bull; فقدان الشھیة<br />&bull; حُمى<br />&bull; الطفح الجلدي الذي قد یكون حكة<br />&bull; السعال<br />الآثار الجانبیة الشائعة التي قد تظھر في فحوصات الدم ھي:<br />&bull; انخفاض عدد خلایا الدم الحمراء (فقر الدم) الذي یمكن أن یسبب التعب والصداع وضیق التنفس<br />&bull; انخفاض عدد خلایا الدم البیضاء (قلة العدلات) مما یجعلك أكثر عرضة للإصابة بالعدوى<br />&bull; انخفاض مستویات الصودیوم في الدم (نقص صودیوم الدم).<br />&bull; زیادة أنزیمات الكبد.<br />غیر شائعة:<br />تؤثر على ۱ من كل ۱۰۰ شخص:<br />&bull; القلق<br />&bull; الشعور بضربات غیر طبیعیة في القلب (خفقان)<br />&bull; انتفاخ واحمرار في الفم<br />&bull; تساقط الشعر .<br />&bull; بقع حمراء منتفخة على الجلد (شرى).<br />أعراض جانبیة غیر شائعة قد تظھر في فحوصات الدم لدیك:<br />&bull; زیادة في الأمیلیز (إنزیم ینتج في البنكریاس).<br />نادرة:<br />تؤثر على ۱ من كل ۱۰۰۰۰<br />&bull; رؤیة أو سماع أشیاء غیر موجودة (ھلوسة).<br />أعراض جانبیة أخرى.<br />حدثت آثار جانبیة أخرى في عدد قلیل من الناس ولكن شیوعھا الدقیق غیر معروف.<br />&bull; التھاب الكبد<br />&bull; انسداد القنوات الصفراویة (الكولیستاتیس).<br />&bull; زیادة معدل ضربات القلب (تسرع القلب).<br />&bull; التھاب الأوعیة الدمویة الذي قد یظھر على شكل بقع حمراء أو أرجوانیة مرتفعة على الجلد ولكن یمكن أن تؤثر على أجزاء<br />أخرى من الجسم.<br />&bull; نوبات.<br />&bull; نوبات ذعر , بكاء<br />&bull; كوابیس<br />&bull; مشكلة صحیة نفسیة شدیدة یفقد فیھا الشخص الاتصال بالواقع ولا یستطیع التفكیر والحكم بوضوح<br />&bull; عسر الھضم<br />&bull;&bull;<br />قرحة الفم<br />&bull; بثور<br />&bull; تقشیر الجلد<br />&bull; زیادة حساسیة الجلد لأشعة الشمس<br />أعراض جانبیة أخرى قد تظھر في فحوصات الدم:<br />&bull; نقص في جمیع أنواع خلایا الدم (قلة الكریات الشاملة).<br />الإبلاغ عن الآثار الجانبیة:<br />&bull; إن كان لدیك أعراض جانبیة أو لاحظت أعراض جانبیة غیر مذكورة في ھذه النشرة، فضلًا ابلغ الطبیب أوالصیدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یحفظ في درجة حرارة أقل من ۳۰ درجة مئویة.<br />&bull; مدة الصلاحیة ۲٤ شھرا.<br />&bull; یحفظ في العبوة الأصلیة لحمایتھ من الرطوبة.<br />&bull; احفظ ھذا الدواء بعیدًا عن رؤیة ومتناول أیدي الأطفال.<br />یشیر تاریخ انتھاء الصلاحیة إلى الیوم .EXP &bull; لا تستخدم ھذا الدواء بعد تاریخ انتھاء الصلاحیة المذكور على العبوة بعد<br />الأخیر من الشھر.<br />&bull; لا تتخلص من الأدویة في میاه الصرف الصحي أو النفایات المنزلیة. اسأل الصیدلي عن كیفیة التخلص من الأدویة التي لم تعد<br />بحاجة إلیھا. ستساعد ھذه الإجراءات في حمایة البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة ھي أتوفاكوین و برو جوانیل ھیدروكلورید<br />(L-HPC ھیدروكسیل بروبیل السلیلوز منخفض الاستبدال ، ( PH الصواغات الأخرى ھي: السلیلوز ، دقیق التبلور (أفیسیل 101<br />، ( السیلیكا الغرویة اللامائیة (أیلیروس ۲۰۰ ) ، بوفیدون (كولیدون - ۳۰ ، (Primojel) نشا الصودیوم جلایكولات ،LH 21)<br />ستیرات الماغنیسیوم ، (L-HPC LH ھیدروكسیل بروبیل سلیلوز منخفض الاستبدال ( 11 ،Poloxamers (Lutrol F 68)<br />والمیاه النقیة.<br />HPMC ثاني أكسید التیتانیوم ، / 2910 ،cP ھیبرمیلوز ۳ : HPMC الصواغات الأخرى لطبقة الكسوة الخارجیة ھي: / 2910<br />أكسید الحدید ، / PEG ماكروجول 400 ، / PEG ماكروجول 8000 ، cP ھیبرمیلوز ٥۰ HPMC 2910 / ،cP ھیبرمیلوز ۱٥<br />الأحمر</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">مالاكون أقراص ( ۲٥۰ ملجرام / ۱۰۰ ملجرام)<br />H&quot; أقراص مستدیرة ، مطلیة باللون الوردي ، محدبة الوجھین ، منقوش علیھا حرف &quot; على جانب واحد و &quot; ۱۷٥ &quot; على الجانب الآخر.<br />كیفیة توفیر مالاكون أقراص؟<br />.(&#39;۱۰&times; یتم توفیر أقراص مالاكون ۲٥۰ ملجرام/ ۱۰۰ ملجرام في عبوات تحتوي على شریط واحد بھ ۱۰ أقراص (</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة أماروكس السعودیة الصناعیة<br />شارع الجامعة ، حي الملز<br />الریاض ۱۲٦۲۹ ، المملكة العربیة السعودیة<br />+966 11 226 الھاتف والفاكس: 8850<br />المصنع<br />ھتیرو لاب المحدودة - الوحدة الخامسة - الھند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة ھذه النشرة في ینایر ۲۰۲٤ ، نسخة 1
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Atovaquone and proguanil hydrochloride 62.5mg/25mg Film-coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each Atovaquone and proguanil hydrochloride Film-coated Tablets contains 62.5mg Atovaquone and 25mg proguanil hydrochloride
Excipient(s) with known effect
For full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated Tablets
Pink, round, biconvex film coated tablets, debossed with 'I' on one side and '11' on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prophylaxis of Plasmodium falciparum malaria in adults and children weighing 11-40 kg.<br />Treatment of acute, uncomplicated Plasmodium falciparum malaria in adults and in children weighing &ge; 5 kg and &lt;11kg.<br />Official guidelines and local information on the prevalence of resistance to antimalarial drugs should be taken into consideration. Official guidelines will normally include WHO and public health authorities&#39; guidelines</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />The dosage for the prophylaxis and treatment of acute, uncomplicated P. falciparum malaria in children is based on body weight.<br />Prophylaxis<br />Dosage in individuals weighing 11-40 kg</p><p>Dosage/day<br />Body Weight Range((kg)<br />Atovaquone<br />(mg)<br />Proguanil (mg)<br />No of Tablets<br />11-20<br />62.5<br />25<br />One Atovaquone and proguanil<br />21-30<br />125<br />50<br />Two Atovaquone and proguanil<br />31-40<br />187.5<br />75<br />Three Atovaquone and proguanil<br />&gt;40<br />250<br />100<br />Subjects of &gt;40 kg should receive ONE Atovaquone and proguanil hydrochloride 250/100 mg tablet daily<br />The safety and effectiveness of Atovaquone and proguanil hydrochloride paediatric tablets for prophylaxis of malaria in children who weigh less than 11 kg has not been established.<br />Prophylaxis should<br />&bull; commence 24 or 48 hours prior to entering a malaria-endemic area,<br />&bull; continue during the period of the stay,<br />&bull; continue for 7 days after leaving the area.<br />The safety and effectiveness of Atovaquone and proguanil hydrochloride has been established in studies of up to 12 weeks in residents (semi-immune subjects) of endemic areas (see section 5.1).<br />In non-immune subjects, the average duration of exposure in clinical studies was 27 days.<br />Treatment<br />Dosage in individuals weighing 5-&lt;11 kg&nbsp;</p><p>Dosage/day<br />Body Weight Range (kg)<br />Atovaquone (mg)<br />Proguanil (mg)<br />No of Tablets<br />5-8<br />125<br />50<br />Two Atovaquone paediatric tablets daily for 3 consecutive days<br />9-10<br />187.5<br />75<br />Three Atovaquone paediatric tablets daily for 3 consecutive days.<br />&ge; 11<br />Refer to Atovaquone 250/100 mg Tablets SmPC&nbsp;</p><p>The safety and effectiveness of Atovaquone and proguanil hydrochloride paediatric tablets for the treatment of malaria in children who weigh less than 5 kg has not been established.<br />For individuals who weigh 11 kg or more, the first choice for the treatment of acute, uncomplicated P. falciparum malaria is Atovaquone and proguanil hydrochloride tablets (250/100 mg). Please consult the Atovaquone and proguanil hydrochloride tablets SmPC for the recommended dosage for this weight range. Atovaquone and proguanil hydrochloride tablets are four-times the strength of Atovaquone and proguanil hydrochloride paediatric tablets.<br />In circumstances when sufficient atovaquone and proguanil hydrochloride tablets are not available, then Atovaquone and proguanil hydrochloride paediatric tablets may be used.<br />Hepatic Impairment<br />There are no studies in children with hepatic impairment. However, a pharmacokinetic study in adults indicates that no dosage adjustments are needed in patients with mild to moderate hepatic impairment. Although no studies have been conducted in patients with severe hepatic impairment, no special precautions or dosage adjustment are anticipated (see section 5.2).<br />Renal Impairment<br />There are no studies in children with renal hepatic impairment. However, a pharmacokinetic study in adults indicate that no dosage adjustments are needed in those with mild to moderate renal impairment. Due to the lack of information regarding appropriate dosing, atovaquone and proguanil hydrochloride is contraindicated for the prophylaxis of malaria in adults and children with severe&nbsp;renal impairment (creatinine clearance &lt;30 mL/min; see sections 4.3 and 5.2).<br />Method of administration<br />The daily dose should be taken once daily with food or a milky drink (to ensure maximum absorption) at the same time each day.<br />If patients are unable to tolerate food Atovaquone/Proguanil Hydrochloride paediatric tablets should be administered, but systemic exposure of atovaquone will be reduced. In the event of vomiting within 1-hour of dosing a repeat dose should be taken.<br />Atovaquone/Proguanil Hydrochloride paediatric tablets should preferably be swallowed whole. If difficulties are encountered when dosing young children, the tablets may be crushed and mixed with food or a milky drink just prior to administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
Atovaquone and proguanil hydrochloride tablets are contraindicated for prophylaxis of P. falciparum malaria in patients with severe renal impairment (creatinine clearance <30 mL/min).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Persons taking atovaquone and proguanil hydrochloride for prophylaxis or treatment of malaria should take a repeat dose if they vomit within 1 hour of dosing. In the event of diarrhoea, normal dosing should be continued. Absorption of atovaquone and proguanil hydrochloride may be reduced in individual with diarrhoea or vomiting, but diarrhoea or vomiting was not associated with reduced efficacy in clinical trials of Atovaquone and proguanil hydrochloride for malaria prophylaxis. However, as with other antimalarial agents, subjects with diarrhoea or vomiting should be advised to continue with malaria prevention measures by complying with personal protection measures (repellents, bednets).<br />In patients with acute malaria who present with diarrhoea or vomiting, alternative therapy should be considered. If Atovaquone and proguanil hydrochloride is used to treat malaria in these patients,&nbsp;</p><p>parasitaemia and the patient&#39;s clinical condition should be closely monitored.<br />Atovaquone and proguanil hydrochloride has not been evaluated for the treatment of cerebral malaria or other severe manifestations of complicated malaria including hyperparasitaemia, pulmonary oedema or renal failure. Occasionally, severe allergic reactions (including anaphylaxis) have been reported in patients taking Atovaquone and proguanil hydrochloride. If patients experience an allergic reaction (see section 4.8) Atovaquone and proguanil hydrochloride should be discontinued promptly and appropriate treatment initiated.<br />Atovaquone and proguanil hydrochloride has been shown to have no efficacy against hypnozoites of Plasmodium vivax as parasite relapse occurred commonly when P. vivax malaria was treated with Atovaquone and proguanil hydrochloride alone. Travellers with intense exposure to P. vivax or P. ovale, and those who develop malaria caused by either of these parasites, will require additional treatment with a drug that is active against hypnozoites.<br />In the event of recrudescent infections due to P. falciparum after treatment with Atovaquone and proguanil hydrochloride, or failure of chemoprophylaxis with Atovaquone and proguanil hydrochloride, patients should be treated with a different blood schizonticide as such events can reflect a resistance of the parasite.<br />Parasitaemia should be closely monitored in patients receiving concurrent tetracycline (see section 4.5). The concomitant administration of atovaquone and proguanil hydrochloride and efavirenz or boosted protease-inhibitors should be avoided whenever possible (see section 4.5).<br />The concomitant administration of Atovaquone and proguanil hydrochloride and rifampicin or rifabutin is not recommended (see section 4.5).<br />Concurrent use of metoclopramide is not recommended. Another antiemetic treatment should be given (see section 4.5).<br />Caution is advised when initiating or withdrawing malaria prophylaxis or treatment with Atovaquone and proguanil hydrochloride in patients on continuous treatment with warfarin and other coumarin&nbsp;based anticoagulants (see section 4.5).<br />Atovaquone and proguanil hydrochloride can increase the levels of etoposide and its metabolite (see section 4.5).<br />In patients with severe renal impairment (creatinine clearance &lt;30 mL/min) alternatives to Atovaquone and proguanil hydrochloride for treatment of acute P. falciparum malaria should be recommended whenever possible (see sections 4.2, 4.3 and 5.2).<br />The safety and effectiveness of atovaquone and proguanil hydrochloride tablets for the prophylaxis of malaria in children who weigh less than 11kg and the treatment of malaria in children who weigh less than 5 kg have not been established.<br />Atovaquone and proguanil hydrochloride paediatric tablets are not indicated for the treatment of acute uncomplicated P. falciparum malaria in individuals weighing 11-40 kg. Atovaquone and proguanil hydrochloride tablets should be used in these individuals (see section 4.2).<br />This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant administration of rifampicin or rifabutin is not recommended as it is known to reduce plasma concentrations of atovaquone and proguanil hydrochloride levels by approximately 50% and 34%, respectively (see section 4.4).<br />Concomitant treatment with metoclopramide has been associated with a significant decrease (about 50%) in plasma concentrations of atovaquone and proguanil hydrochloride. Another antiemetic treatment should be given.<br />Although some children have received concomitant atovaquone and proguanil hydrochloride and metoclopramide in clinical trials without any evidence of decreased protection against malaria, the possibility of a clinically significant drug interaction cannot be ruled out.<br />When given with efavirenz or boosted protease-inhibitors, atovaquone and proguanil hydrochloride concentrations have been observed to decrease as much as 75%. This combination should be avoided&nbsp;whenever possible (see section 4.4).<br />Proguanil may potentiate the anticoagulant effect of warfarin and other coumarin based anticoagulants which may lead to an increase in the risk of haemorrhage. The mechanism of this potential drug interaction has not been established. Caution is advised when initiating or withdrawing malaria prophylaxis or treatment with atovaquone- proguanil in patients on continuous treatment with oral anticoagulants. The dose of the oral anticoagulant may need to be adjusted during atovaquone-proguanil treatment or after its withdrawal, based on INR results.<br />Concomitant treatment with tetracycline has been associated with decreases in plasma concentrations of atovaquone and proguanil hydrochloride.<br />The co-administration of atovaquone and proguanil hydrochloride at doses of 45mg/kg/day in children (n=9) with acute lymphoblastic leukaemia for prophylaxis of PCP was found to increase the plasma concentrations (AUC) of etoposide and its metabolite etoposide catechol by a median of 8.6% (P=0.055) and 28.4% (P=0.031) (respectively compared to the co-administration of etoposide and sulfamethoxazole-trimethoprim). Caution should be advised in patients receiving concomitant therapy with etoposide (see section 4.4).<br />Proguanil is primarily metabolised by CYP2C19. However, potential pharmacokinetic interactions with other substrates, inhibitors (e.g., moclobemide, fluvoxamine) or inducers (e.g. artemisinin, carbamazepine) of CYP2C19 are unknown (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy The safety of atovaquone and proguanil hydrochloride when administered concurrently for use in human pregnancy has not been established and the potential risk is unknown.<br />Animal studies showed no evidence for teratogenicity of the combination.<br />The individual components have shown no effects on parturition or pre- and post-natal development. Maternal toxicity was seen in pregnant rabbits during a teratogenicity study (see section 5.3). The use of Atovaquone and proguanil hydrochloride in pregnancy should only be considered if the&nbsp;expected benefit to the mother outweighs any potential risk to the foetus.<br />The Proguanil acts by inhibiting parasitic dihydrofolate reductase. There are no clinical data indicating that folate supplementation diminishes drug efficacy. For women of childbearing age receiving folate supplements to prevent neural tube birth defects, such supplements should be continued while taking fixed dose combination of atovaquone and proguanil tablets.<br />Breast-feeding The atovaquone and proguanil hydrochloride concentrations in milk, in a rat study, were 30% of the concurrent atovaquone and proguanil hydrochloride concentrations in maternal plasma. It is not known whether atovaquone and proguanil hydrochloride is excreted in human milk. Proguanil is excreted in human milk in small quantities.<br />Atovaquone and proguanil hydrochloride paediatric tablets should not be taken by breast-feeding women.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dizziness has been reported. Patients should be warned that if affected they should not drive, operate machinery or take part in activities where this may put themselves or others at risk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical trials of atovaquone and proguanil hydrochloride paediatric tablets for prophylaxis of malaria, 357 children or adolescents 11 to &le;40 kg body weight received atovaquone and proguanil hydrochloride paediatric tablets. Most of these were residents of endemic areas and took atovaquone and proguanil hydrochloride paediatric tablets for about 12 weeks. The rest were travelling to endemic areas, and most took atovaquone and proguanil hydrochloride paediatric tablets for 2-4 weeks.<br />Open label clinical studies investigating the treatment of children weighing between &ge;5 kg and &lt;11 kg have indicated that the safety profile is similar to that in children weighing between 11 kg and 40 kg, and adults.<br />There are limited long term safety data in children. In particular, the long-term effects of atovaquone and proguanil hydrochloride on growth, puberty and general development have not been studied.&nbsp;</p><p>In clinical trials of atovaquone and proguanil hydrochloride in the treatment of malaria the most commonly reported adverse reactions were abdominal pain, headache, anorexia, nausea, vomiting, diarrhoea and coughing.<br />In clinical trials of atovaquone and proguanil hydrochloride for prophylaxis of malaria, the most commonly reported adverse reactions were headache, abdominal pain and diarrhoea.<br />The following table provides a summary of adverse reactions that have been reported to have a suspected (at least possible) causal relationship to treatment with atovaquone and proguanil hydrochloride -proguanil in clinical trials and spontaneous post-marketing reports. The following convention is used for the classification of frequency: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); not known (cannot be estimated from the available data).<br />System Organ Class<br />Very Common<br />Common<br />Uncommon<br />Rare<br />Not known2<br />Blood and lymphatic disorders<br />Anaemia Neutropenia1<br />Pancytopenia<br />Immune system disorders<br />Allergic reactions<br />Angioedema3<br />Anaphylaxis<br />(see section 4.4) Vasculitis3<br />Metabolism and nutrition disorders<br />Hyponatraemia1<br />Anorexia<br />Elevated amylase levels1<br />Psychiatric disorders<br />Abnormal dreams Depression<br />Anxiety<br />Hallucinations<br />Panic attack Crying Nightmares Psychotic disorder<br />Nervous system disorders<br />Headache<br />Insomnia Dizziness<br />Seizure<br />Cardiac disorders<br />Palpitations<br />Tachycardia</p><p>Gastrointestinal disorders<br />Nausea1<br />Vomiting Diarrhoea Abdominal pain<br />Stomatitis<br />Gastric intolerance3<br />Oral ulceration3<br />Hepatobiliary disorders<br />Elevated liver enzymes1<br />Hepatitis Cholestasis 3<br />Skin and subcutaneous tissue disorders<br />Pruritus Rash<br />Hair loss Urticaria<br />Stevens-Johnson syndrome Erythema multiforme Blister Skin exfoliation Photosensitivity reactions<br />General disorders and administration site conditions<br />Fever<br />Respiratory, thoracic and mediastinal<br />Cough<br />1. Frequency taken from atovaquone and proguanil hydrochloride label. Patients participating in clinical trials with atovaquone and proguanil hydrochloride have received higher doses and have often had complications of advance Human Immunodeficiency Virus (HIV) disease. These events may have been seen at a lower frequency or not at all in clinical trials with atovaquone and proguanil hydrochloride.<br />2. Observed from post-marketing spontaneous reports and the frequency is therefore unknown<br />3. Observed with proguanil.</p><p>&nbsp;</p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />&minus; Fax: +966-11-2038222<br />&minus; Call NPC at +966-11-2038222, Ext 2317-2356-2340<br />&minus; SFDA Call Center: 19999<br />&minus; E-mail: npc.drug@sfda.gov.sa<br />&minus; Website: https: //ade.sfda.gov.sa/<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at Website:https: //ade.sfda.gov.sa/<br />To report any side effect(s):<br />Saudi Arabia:<br />o Other GCC States:<br />- Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is insufficient experience to predict the consequences or suggest specific management of atovaquone and proguanil hydrochloride overdose. However, in the reported cases of atovaquone and proguanil hydrochloride overdose, the observed effects were consistent with known undesirable effects of the drug. If overdose occurs, the patient should be monitored and standard supportive treatment applied.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic Group: Antimalarials,<br />ATC Code: P01B B51<br />Mode of Action<br />The constituents of combination tablet of atovaquone and proguanil hydrochloride paediatric tablets, atovaquone and proguanil hydrochloride, interfere with two different pathways involved in the biosynthesis of pyrimidines required for nucleic acid replication. The mechanism of action of atovaquone and proguanil hydrochloride against P. falciparum is via inhibition of mitochondrial electron transport, at the level of the cytochrome bc1 complex, and collapse of mitochondrial membrane potential. One mechanism of action of atovaquone and proguanil hydrochloride, via its metabolite cycloguanil, is inhibition of dihydrofolate reductase, which disrupts deoxythymidylate synthesis. Proguanil also has antimalarial activity independent of its metabolism to cycloguanil, and Proguanil, but not cycloguanil, is able to potentiate the ability of Atovaquone and proguanil hydrochloride to collapse mitochondrial membrane potential in malaria parasites. This latter mechanism may contribute to the antimalarial synergy seen when atovaquone and proguanil hydrochloride and proguanil are used in combination.<br />Microbiology Atovaquone and proguanil hydrochloride has potent activity against Plasmodium spp (in vitro IC50 against P. falciparum 0.23-1.43 ng/mL).<br />Cross-resistance between atovaquone and proguanil hydrochloride and antimalarial agents of other drug classes was not detected among more than 30 P. falciparum isolates, isolates that demonstrated resistance in vitro to one or more of chloroquine (41% of isolates), quinine (32% of isolates), mefloquine (29% of isolates), and halofantrine (48% of isolates).<br />The IC50 of the primary metabolite of proguanil-cycloguanil against various P. falciparum strains was 4-20 ng/mL; some activity of proguanil and another metabolite, 4-chlorophenylbiguanide, is&nbsp;seen in vitro at 600-3000 ng/mL).<br />The combination of atovaquone and proguanil hydrochloride was shown to be synergistic against P. falciparum in vitro. The combination was more effective than either drug alone in clinical studies of the treatment of malaria in both immune and non-immune patients.<br />Clinical Efficacy<br />Prophylaxis<br />The efficacy in non-immune paediatric travellers has not been directly established, but may be assumed through extrapolation by the results on safety and efficacy in studies of up to 12 weeks in paediatric residents (semi-immune) of endemic areas, and from results of safety and efficacy in both semi immune and non immune adults.<br />Data in the paediatric population are available from two trials that primarily evaluated the safety of atovaquone and proguanil hydrochloride paediatric tablets in (non-immune) travellers to endemic areas. In these trials, a total of 93 travellers weighing &lt;40 kg was given atovaquone and proguanil hydrochloride and 93 received another prophylactic antimalarial regimen (81 chloroquine/ proguanil and 12 mefloquine). The majority of travellers went to Africa and the mean duration of stay was between 2-3 weeks. There were no cases of malaria recorded in any subjects who took part in these studies.<br />Treatment<br />An open-label, randomised, parallel-group trial was undertaken in Gabon in 200 children weighing &ge;5 kg and &lt;11 kg with confirmed, uncomplicated P. falciparum malaria. Treatment was with atovaquone and proguanil hydrochloride paediatric tablets or amodiaquine suspension.<br />In the intent-to-treat population, the 28-day cure rate was 87% in the atovaquone and proguanil hydrochloride group (87/100 subjects). In the per-protocol population, the 28-day cure rate was 95% in the atovaquone and proguanil hydrochloride group (87/92 subjects). The parasitological cure rates for the atovaquone and proguanil hydrochloride group were 88% and 95% for the ITT and PP populations, respectively.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no pharmacokinetic interactions between atovaquone and proguanil hydrochloride and proguanil at the recommended doses.<br />In prophylaxis clinical trials where children have received atovaquone and proguanil hydrochloride dosed by bodyweight, trough levels of atovaquone and proguanil hydrochloride, proguanil and cycloguanil in children are generally within the range observed in adults (see following table).<br />Trough Plasma Concentrations [Mean &plusmn; SD, (range)] of Atovaquone and proguanil hydrochloride, Proguanil and Cycloguanil during Prophylaxis with atovaquone and proguanil hydrochloride in Children* and Adults<br />Atovaquone and proguanil hydrochloride: Proguanil HCL Daily Dose<br />[Weight Category]<br />62.5 mg:25 mg<br />[11-20 kg]<br />125 mg:50 mg<br />[21-30 kg]<br />187.5 mg:75 mg<br />[31-40 kg]<br />250mg:100 mg<br />Adult (&gt; 40 kg)<br />Atovaquone and<br />2.2 + 1.1<br />3.2 + 1.8<br />4.1 + 1.8<br />2.1 + 1.2<br />(0.2-5.8)<br />(0.2-10.9)<br />(0.7-8.8)<br />(0.1-5.7)<br />No. Subjects<br />n=87<br />n=88<br />n=76<br />n=100<br />Proguanil (&mu;g/mL)<br />12.3 + 14.4<br />18.8 + 11.2<br />26.8 + 17.1<br />26.8 + 14.0<br />(&lt;5.0-14.3)<br />(&lt;5.0-87.0)<br />(5.1-55.9)<br />(5.2-73.2)<br />No. Subjects<br />n=72<br />n=83<br />n=75<br />n=95<br />Cycloguanil (ng/mL)<br />7.7 + 7.2<br />8.1 + 6.3<br />8.7 + 7.3<br />10.9 + 5.6<br />(&lt;5.0-43.5)<br />(&lt;5.0-44.1)<br />(6.4-17.0)<br />(5.0-37.8)<br />No. Subjects<br />n=58<br />n=69<br />n=66<br />n=95<br />* Pooled data from two studies<br />Absorption<br />Atovaquone and proguanil hydrochloride is a highly lipophilic compound with low aqueous solubility. Although there are no atovaquone and proguanil hydrochloride bioavailability data in healthy subjects, in HIV-infected patients the absolute bioavailability of a 750 mg single dose of atovaquone and proguanil hydrochloride tablets taken with food is 21% (90% CI: 17% - 27%).<br />Dietary fat taken with atovaquone and proguanil hydrochloride increases the rate and extent of absorption, increasing AUC 2-3 times and Cmax 5 times over fasting. Patients are recommended to&nbsp;take atovaquone and proguanil hydrochloride paediatric tablets with food or a milky drink (see section 4.2).<br />Proguanil hydrochloride is rapidly and extensively absorbed regardless of food intake.<br />Distribution<br />Apparent volume of distribution of atovaquone and proguanil hydrochloride and proguanil is a function of bodyweight. Atovaquone and proguanil hydrochloride is highly protein bound (&gt;99%) but does not displace other highly protein bound drugs in vitro, indicating significant drug interactions arising from displacement are unlikely.<br />Following oral administration, the volume of distribution of atovaquone and proguanil hydrochloride and proguanil is approximately 8.8 L/kg.<br />Proguanil is 75% protein bound. Following oral administration, the volume of distribution of proguanil in adults and children (&gt;5 kg) ranged from 20 to 79 L/kg.<br />In human plasma the binding of atovaquone and proguanil hydrochloride and proguanil was unaffected by the presence of the other.<br />Biotransformation<br />There is no evidence that atovaquone and proguanil hydrochloride is metabolised, and there is negligible excretion of atovaquone and proguanil hydrochloride in urine with the parent drug being predominantly (-&gt;-90%) eliminated unchanged in faeces.<br />Proguanil hydrochloride is partially metabolised, primarily by the polymorphic cytochrome P450 isoenzyme 2C19, with less than 40% being excreted unchanged in the urine. Its metabolites, cycloguanil and 4-chlorophenylbiguanide, are also excreted in the urine.<br />During administration of atovaquone and proguanil hydrochloride at recommended doses proguanil metabolism status appears to have no implications for treatment or prophylaxis of malaria.<br />Elimination<br />The elimination half life of atovaquone and proguanil hydrochloride is 1-2 days in children.<br />The elimination half lives of proguanil and cycloguanil are each about 12-15 hours in children.<br />Oral clearance for atovaquone and proguanil hydrochloride increases with increased body weight and is about 70% higher in a 40 kg subject relative to a 20 kg subject. The mean oral clearance in&nbsp;paediatric and adult patients weighing 5 to 40 kg ranged from 0.5 to 6.3 L/h for atovaquone and from 8.7 to 64 L/h for proguanil hydrochloride.<br />Pharmacokinetics in renal impairment<br />There are no studies in children with renal impairment.<br />In adult patients with mild to moderate renal impairment, oral clearance and/or AUC data for atovaquone and proguanil hydrochloride, proguanil and cycloguanil are within the range of values observed in patients with normal renal function.<br />Atovaquone and proguanil hydrochloride Cmax and AUC are reduced by 64% and 54%, respectively, in adult patients with severe renal impairment (&lt;30 mL/min/1.73 m2).<br />In adult patients with severe renal impairment, the elimination half lives for proguanil (t&frac12; 39 hours) and cycloguanil (t&frac12; 37 hours) are prolonged, resulting in the potential for drug accumulation with repeated dosing (see sections 4.2 and 4.4).<br />Pharmacokinetics in hepatic impairment<br />There are no studies in children with hepatic impairment.<br />In adult patients with mild to moderate hepatic impairment, there is no clinically significant change in exposure to atovaquone and proguanil hydrochloride when compared to healthy patients. In adult patients with mild to moderate hepatic impairment there is an 85% increase in proguanil AUC, with no change in elimination half life, and there is a 65-68% decrease in Cmax and AUC for cycloguanil.<br />No data are available in adult patients with severe hepatic impairment (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Repeat dose toxicity:<br />Findings in repeat dose toxicity studies with atovaquone/ proguanil hydrochloride combination were entirely proguanil- related and were observed at doses providing no significant margin of exposure in comparison with the expected clinical exposure. However, as proguanil has been used extensively and safely in the treatment and prophylaxis of malaria at doses similar to those used in the combination, these findings are considered of little relevance to the clinical situation.</p><p>Reproductive toxicity studies:<br />In rats and rabbits there was no evidence of teratogenicity for the combination. No data are available regarding the effects of the combination on fertility or pre- and post-natal development, but studies on the individual components of atovaquone and proguanil hydrochloride have shown no effects on these parameters. In a rabbit teratogenicity study using the combination, unexplained maternal toxicity was found at a systemic exposure similar to that observed in humans following clinical use.<br />Mutagenicity: A wide range of mutagenicity tests have shown no evidence that atovaquone or proguanil have mutagenic activity as single agents.<br />Mutagenicity studies have not been performed with atovaquone and proguanil hydrochloride in combination with proguanil.<br />Cycloguanil, the active metabolite of proguanil, was also negative in the Ames test, but was positive in the Mouse Lymphoma assay and the Mouse Micronucleus assay. These positive effects with cycloguanil (a dihydrofolate antagonist) were significantly reduced or abolished with folinic acid supplementation.<br />Carcinogenicity: Oncogenicity studies of atovaquone and proguanil hydrochloride alone in mice showed an increased incidence of hepatocellular adenomas and carcinomas. No such findings were observed in rats and mutagenicity tests were negative. These findings appear to be due to the inherent susceptibility of mice to atovaquone and proguanil hydrochloride and are considered of no relevance in the clinical situation.<br />Oncogenicity studies on proguanil alone showed no evidence of carcinogenicity in rats and mice. Oncogenicity studies on proguanil in combination with atovaquone and proguanil hydrochloride have not been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>6.1 List of excipients<br />Atovaquone and proguanil hydrochloride:<br />The other ingredients are: Cellulose, microcrystalline (Avicel PH 101), Low-Substituted Hydroxylpropyl cellulose (L-HPC LH 21), Sodium starch glycolate (Primojel), Silica colloidal anhydrous (Aerosil 200), Povidone (kollidon-30), Poloxamers (Lutrol F 68), Low-Substituted Hydroxylpropyl cellulose (L-HPC LH 11), Magnesium Stearate and Purified Water.<br />Film coating composition: HPMC 2910/Hypromellose 3cP, Titanium Dioxide, HPMC 2910/Hypromellose 15cP, HPMC 2910/Hypromellose 50 cP, Macrogol/PEG 8000, Macrogol/PEG 400, Iron Oxide Red.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10&rsquo;s Blister Pack.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.<br />Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Amarox Industrial Company
Al Jamiah Street, Al Malaz District
Riyadh 12629, Saudi Arabia.
Tel & Fax: +966 11 226 8850.
Manufacture
Hetero Labs Limited Unit V, India.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April.2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>